Trevena Inc TRVN

Healthcare Biotechnology

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).

OTCPK:TRVN - Post by User

Trevena Inc

Bullboard Posts

Comment by jagsfan2on Nov 17, 2017 11:07am

41 Views

Post# 26983968

RE:Gettin' JAGGY wit it...

GG; " Let's keep this thread to TRVN and NOT WEASEL WHACK with off topics."

I don't see anything that's 'off-topic' in my post.
It just deals with move up in SP & Gowen's part in opioid meeting (assume it has been sparked by Trump's claim to do something about opioid epidemic in North America).
The appearance by TRVN's CEO raises TRVN's status in the pain-killer sector of Pharma mkt.
It also puts TRVN in the picture for investors, single, fund or competitors.

I can see that you'll have no wish to see TRVN bought out in its nursery days at the present low SP but I doubt that will happen.
More likely that a larger company may take a position to negotiate sales/marketing contract or simply to increase the diversity of what they offer in the pharma marketplace.

Bullboard Posts

Gold vs. bitcoin, where should you invest?